AffiliationOpsona Therapeutics Ltd., Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St. James' Hospital, Dublin 8, Ireland. firstname.lastname@example.org
Immune System Diseases/*immunology/therapy
Molecular Targeted Therapy
MetadataShow full item record
CitationTrends Pharmacol Sci. 2011 Jul;32(7):435-42. Epub 2011 Apr 27.
JournalTrends in pharmacological sciences
AbstractSince the identification of the first Toll-like receptor (TLR) in humans in 1997, understanding of the molecular basis for innate immunity has increased significantly. The TLR family and downstream signalling pathways have been extensively characterised, There is now significant evidence suggesting a role for TLRs in human inflammatory and immune diseases such as rheumatoid arthritis, diabetes, allergy/asthma and atherosclerosis. Various approaches have been taken to identify novel therapeutic agents targeting TLRs including biologics, small molecules and nucleic acid-based drugs. Several are now being evaluated in the clinic and showing promise against various diseases. This review paper outlines the recent advances in the understanding of TLR biology and highlights novel TLR agonists and antagonists in development for the treatment of immune diseases.
- The role of Toll-like receptors in immune disorders.
- Authors: Uematsu S, Akira S
- Issue date: 2006 Mar
- Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease?
- Authors: Katsargyris A, Klonaris C, Bastounis E, Theocharis S
- Issue date: 2008 Nov
- The role of toll-like receptors in chronic inflammation.
- Authors: Drexler SK, Foxwell BM
- Issue date: 2010 Apr
- New developments in Toll-like receptor targeted therapeutics.
- Authors: Connolly DJ, O'Neill LA
- Issue date: 2012 Aug
- Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets.
- Authors: Cole JE, Mitra AT, Monaco C
- Issue date: 2010 Nov